Dellann Elliott Mydland

The EndBrainCancer Initiative wants patient concerns reflected in national treatment guidelines.

An easier application process could make experimental drugs more accessible to patients in need — outside the realm of clinical trials.

Dellann Elliott Mydland, founder and president of the EndBrainCancer Initiative and 2016 GBM Hero, discusses how miracles do happen in the world of glioblastoma multiforme (GBM), and people survive.

Could immediate access to care be the turning point?

Dellann Elliott Mydland, from the Chris Elliott Fund, discusses testing brain tumor tissue before surgery.

2015 started off with a bang, with a focus on brain cancer patients and new treatment options for recurrent glioblastoma (rGBM).